N/A N=258 Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)
Hepatitis C, Chronic
Primary: Percentage of Participants With Relapse At 24 Weeks After the End Of Treatment (EOT) — 13.65 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=79 Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
Hepatitis C
Primary: Patients Who Are Negative for Hepatitis C Virus (HCV) RNA at 3 Months Post-transplant: Intent-to-Treat Analysis (ITT) — 0; 5; 6 participants — p=0.0477
Phase 4 N=92 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
Hepatitis C · Liver Transplantation
Primary: Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted…
Phase 2 N=40 Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant
Recurrent Chronic Hepatitis C Virus · Post Liver Transplant
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 70.0 percentage of participants
Phase 4 N=35 Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin
Chronic Hepatitis C · Hemodialysis
Primary: 1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs) — 13; 8…
N/A N=496 Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
Hepatitis C
Primary: Number of HCV LVL G1 Participants Who Relapsed — 16 Participants
N/A N=2 Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)
Hepatitis C
Primary: Number of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Levels During Part 2 of the Study — 0; 2; 2; 2 participants
Phase 4 N=58 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
Hepatitis C
Primary: Virological Response (Intention to Treat) — 19; 21; 7; 2 participants
Phase 2 N=21 High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
Chronic Hepatitis C
Primary: Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy. — 3 participants
Phase 2 N=229 Combination Therapy for Chronic Hepatitis C Infection
Hepatitis C, Chronic
Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects
Phase 2 N=72 Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Chronic Hepatitis C
Primary: Number of Participants With Sustained Virologic Response — 70 Participants
N/A N=1,128 Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)
Hepatitis C · Hepatitis C, Chronic
Primary: Number of Participants Not Eligible for Antiviral Treatment by Reason for Non-eligibility — 144; 77; 17; 7 participants
Phase 2 N=129 A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Chronic Hepatitis C Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 97.1; 96.3; 100; 100 percentage of participants
Phase 3 N=1,050 Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
Chronic Hepatitis c · Cirrhosis, Liver · Fibrosis, Liver
Primary: Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase…
Phase 3 N=100 Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)
Chronic Hepatitis c
Primary: Sustained Virologic Response — 24; 25 participants
Phase 2 N=24 Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Change in Serum HCV RNA Viral Titer From Baseline to 28 Days — -0.46; -0.11 log IU/ml
Phase 3 N=36 A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
Chronic Hepatitis C Virus (HCV) Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment — 100 percentage of participants
Phase 4 N=11 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)
Hepatitis C
Primary: Delta Hepatitis C Viral Load — 15 percent change
Phase 2 N=35 New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
Cirrhosis · Chronic Hepatitis C · Hepatitis C
Primary: Changes in Interferon Stimulated Genes in the Liver — -0.04915; -0.35948; -0.49980; -0.79328 relative expression
Phase 3 N=249 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection
Hepatitis C
Primary: Percentage of Participants Maintaining SVR at the Last Available Visit — 100 Percentage of participants
Phase 4 N=377 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Sustained Virologic Response (SVR)Rate — 130; 72 participants — p=< 0.001
Phase 3 N=109 Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
Chronic Hepatitis C
Primary: The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained…
Phase 3 N=125 Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)
Liver Transplantation · Hepatitis C, Chronic · Liver Cirrhosis
Primary: A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment — 36 Participants
Phase 3 N=395 A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Chronic Hepatitis C Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment — 96.3 percentage of participants
Phase 2 N=146 Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C
Hepatitis C
Primary: A Comparison of the Percentage of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of Treatment. — 28.8; 31.5…
Phase 2 N=61 Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Hepatitis C · Hepatocellular Carcinoma
Primary: Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12 — 75.0; 69.8 percentage of participants
N/A N=2,302 Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative Participants at End of Therapy (EoT) — 1306 Participants
Phase 3 N=30 A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
Hepatitis C, Chronic
Primary: Percentage of Participants Who Experienced at Least 1 Adverse Event. — 80.0 Percentage of participants
N/A N=49 A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C
Hepatitis C, Chronic
Primary: Sustained Virological Response (SVR): Percentage of Participants Who Were HCV Seronegative at 6 Months After Completing Therapy — 59.5; 58.3 percentage of participants
Phase 2 N=67 Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
HIV Infection · Hepatitis C Infection
Primary: Percentage of Participants With Complete Early Virologic Response (cEVR) — 38.8 percentage of participants